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Abstract
Background: Claims data are potentially useful for identifying long-acting β-agonist (LABA) use by patients with
asthma, a practice that is associated with increased mortality. We evaluated the accuracy of claims data for classifying
prevalent asthma and chronic obstructive pulmonary disease (COPD) among initiators of LABAs.
Methods: This study included adult LABA initiators during 2005–2008 in a US commercial health plan. Diagnosis codes
from the 6 months before LABA initiation identified potential asthma or COPD and a physician adjudicated case status
using abstracted medical records. We estimated the positive predictive value (PPV) and 95% confidence intervals (CI) of
covariate patterns for identifying asthma and COPD.
Results: We sought 520 medical records at random from 225,079 LABA initiators and received 370 (71%). The PPV
for at least one asthma claim was 74% (CI 63–82), and decreased as age increased. Having at least one COPD claim
resulted in a PPV of 82% (CI 72–89), and of over 90% among older patients, men, and recipients of inhaled
a n t i c h o l i n e r g i cd r u g s .O n l y2 %( C I0 . 2 –7.6) of patients with a claim for COPD alone were found to have both COPD
and asthma, while 9% (CI 4–16) had asthma only. Twenty-one percent (CI 14–30) of patients with claims for both
diagnoses had both conditions. Among patients with no asthma or COPD claims, 62% (CI 50–72) had no confirmed
diagnosis and 29% (CI 19–39) had confirmed asthma.
Conclusions: Subsets of patients with asthma, COPD, and both conditions can be identified and differentiated using
claims data, although categorization of the remaining patients is infeasible. Safety surveillance for off-label use of LABAs
must account for this limitation.
Keywords: Claims data, Risk management, Off-label prescribing, Asthma, Chronic, Obstructive pulmonary disease,
Long-acting beta agonis
Background
Although long-acting β-agonist (LABA) medications im-
prove lung function in asthma and chronic obstructive
pulmonary disease (COPD) by inducing relaxation of
bronchial smooth muscle and inhibiting release of medi-
ators of hypersensitivity [1], their use in asthma, at least
in the absence of concomitant inhaled corticosteroids
(ICS), has been associated with more asthma-related
deaths [2]. These findings, though not uniform [3], have
led to increased regulatory restrictions on the use of
LABA, including the implementation of Risk Evaluation
and Mitigation Strategies (REMS) that aim to inform
prescribers and patients about these risks [4]. Indeed,
some LABAs have only an indication for COPD [5].
Monitoring whether patients with asthma only use
LABAs has the potential to ensure that prescribers are
using the products in accordance with known safety
data. Physicians should generally avoid prescribing
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http://www.biomedcentral.com/1471-2466/14/47LABA as monotherapy for asthma (an “off-label” use),
so that unnecessary harms in patients with asthma are
avoided, while ensuring that the product reaches patients
with COPD (an “on-label” use), in whom LABA risk-
benefit profiles appear acceptable. Health insurance claims
data provide an efficient core for this type of surveillance,
but the data must accurately characterize LABA users’
likely indication for use of the drugs (asthma or COPD).
Indeed, COPD and asthma are distinct clinical entities,
but share symptoms and treatments. COPD is character-
ized by non-reversible airflow restriction or obstruction
due to chronic bronchitis or emphysema [6]. Asthma in-
volves recurrent airway obstruction, hyper-responsiveness,
and inflammation [7]. First onset of asthma generally oc-
curs at a young age, while first onset of COPD typically
occurs among patients over 40 years of age.
The similarities in these conditions complicate dif-
ferentiation of COPD and asthma in claims data. There-
fore the objective of this study was to identify patterns
of health insurance claims for asthma and COPD
among users of LABA (with or without ICS use) that
might improve the categorization of individual patients
with asthma or COPD. We studied only new users of
LABA to quantify the measurement characteristics of
the data for identifying the indication for treatment so
that these data would directly inform safety surveillance
for LABA.
Methods
Data sources
The study population came from the Normative Health
Information Database, a claims database of a large US
commercial health plan (UnitedHealth Care). Diagnoses
associated with the claims are recorded using the Inter-
national Classification of Disease, 9th revision (ICD-9)
coding system. Procedures map to ICD-9, Common Pro-
cedural Terminology (CPT), and the Centers for Medi-
care and Medicaid Services Common Procedure Coding
System (HCPCS) codes. National Drug Codes (NDCs)
identify medications.
Cohort formation
Eligible patients were initiators or switchers of LABA or
LABA and ICS combinations who were at least 20 years
old between 01 January 2005 and 31 December 2008
(Figure 1). We included all LABA and ICS products on
the U.S. market during the study period. The LABAs
were: arformoterol, formoterol, and salmeterol. The ICS
were: beclomethasone, budesonide, ciclesonide, fluniso-
lide, fluticasone, mometasone, and triamcinolone.
We defined initiation as a dispensing of a LABA pre-
ceded by 6 months of continuous enrollment without a
dispensing of the same LABA. Switchers were patients
who initiated a new LABA, but used another LABA during
the previous 6 months. The study began for each patient at
Figure 1 Formation of study cohorts from the Normative Health Information, and Identification and Confirmation of Prevalent Asthma
and COPD, 1/1/2005–12/31/2008. LABA, identifying long-acting β-agonist; ICS, inhaled corticosteroid; COPD, chronic obstructive pulmonary
disease; ICD, International Classification of Diseases.
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months prior to the index date was the period from which
we identified diagnosis, procedure, and medication codes
that characterized the study population. Patients were con-
sidered concomitant users of LABA and ICS upon initi-
ation of a combination LABA/ICS product or if they
initiated a LABA and received a dispensing of an ICS on
the same day.
Patients with a recent previous dispensing of an ICS
were in the monotherapy group. While requiring that
patients received the combination formulation of LABA/
ICS or concomitant ICS on the same day as the initial
LABA dispensing may result in misclassification of indi-
viduals who received ICS and LABA on different days,
this more stringent definition increases the likelihood
that we include only users concomitant therapy in the
combination LABA/ICS group. This preference is im-
portant because combination LABA/ICS for asthma ap-
pears safer than LABA monotherapy and should not be
discouraged. (Empirically, this decision was unimportant.
Ninety-six percent of patients initiated on a combination
product. Of the 9,965 patients classified as LABA-only
initiators, 1,931 [19%] used ICS in the baseline period
and were potentially misclassified. This number repre-
sents only 0.9% of the full study population, and this
misclassification is of little consequence).
Identification of asthma and COPD
Potential cases of asthma or COPD had ICD-9 diagnosis
codes for asthma or COPD in any diagnosis field on claims
occurring in the 6 months prior to the index date on an in-
patient or outpatient claim (a similar approach requiring
12 months of continuous enrollment yielded similar re-
sults). Patients with at least one code for asthma, COPD,
both, or neither in the baseline period were eligible for sub-
sequent medical record abstraction. We excluded from
consideration certain diagnosis codes that might include
COPD, but are mixed with other disorders, including ICD-
9 490 (bronchitis, not specified as acute or chronic) [6]. Be-
cause hospitalization for asthma is rare relative to the
prevalence of the disease, we did not distinguish between
inpatient and outpatient claims. We chose to develop our
own definition of asthma and COPD despite the existence
of algorithms in the literature (e.g., Mapel et al. [8] and
Dombkowski et al. [9]), because in our work we aimed to
classify baseline diagnoses (indications), whereas most defi-
nitions in the literature apply specifically to outcomes or
cohort definitions. Definitions of outcomes and covariates
are more robust to insensitive measures of disease than
case criteria for identification of off-label use.
To verify the diagnoses, we sought a random sample
of 130 medical records (with the goal of obtaining 100)
from each of the following 4 categories of eligible pa-
tients (520 patients in total):
Patients with at least one claim for asthma:
ICD-9 493.xx, asthma
Patients with at least one claim for COPD:
ICD-9 491.2x, obstructive chronic bronchitis
ICD-9 492.8, other emphysema
ICD-9 496, chronic airway obstruction, not elsewhere
classified
Patients with claims for both asthma and COPD
Patients without a claim for either asthma or COPD
We sought a total of 640 records, including alternate
records for 120 of the 520 sampled patients. We sought
medical records from hospitals and physicians’ offices
using a 2-step process. First, we created a chronological
listing of insurance claims for the sampled patients not-
ing the date of service corresponding to the diagnosis
code of interest (asthma or COPD). Patients with claims
for both diagnoses had the one closest to the LABA ini-
tiation date noted, and those with neither had no claim
noted.
These claims listings were reviewed to identify the pro-
vider or facility from which the medical record was likely
to document the diagnosis. Trained abstractors contacted
the provider or facility seeking the medical record. For
records with clearly inadequate information (as assessed
prior to the adjudication process), we re-contacted pro-
viders to request additional information. If additional
information was not obtained for these cases, the charts
were not adjudicated and did not enter analysis. Incom-
plete medical records were those without clinical informa-
tion available (i.e., the contained administrative material
only). Records with clinical information, even if incom-
plete, were forwarded to the adjudicators for review.
A physician external to the study team, blinded to study
medications, adjudicated the presence of asthma and
COPD using the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria for COPD [10] and the third
Expert Panel Report of Guidelines on Asthma [11]. Con-
firmation required the affirmative listing of the case criteria
in the medical records. The Additional file 1 includes add-
itional information on the case adjudication process.
Analysis
We initially tabulated characteristics of the study popu-
lation from the 6 months before LABA initiation, includ-
ing whether LABA initiators were apparent naïve users
of all LABAs, the prevalence of comorbidities, and the
intensity of healthcare utilization characteristics, such as
outpatient visits, emergency department visits, hospita-
lizations, and home oxygen use. Next, we empirically
identified covariates by listing the 100 most prevalent
(top 100) drug classes, top 100 diagnoses (at the 3-digit
ICD-9 level) and the top 100 procedures received by
LABA users, stratifying by ICS.
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then estimated the association between the baseline
characteristics and the adjudicated diagnosis, with the
aim to distinguish between patients with confirmed
asthma and those without, and those with confirmed
COPD and those without.
We estimated the positive predictive value (PPV) of
claims identification of asthma or COPD stratified by
the 3 covariates with the largest absolute difference in
prevalence across patients with confirmed and uncon-
firmed asthma. We use this approach among all patients
except for those with only a claim for COPD. Whereas for
patients with claims for asthma or no claim for asthma or
COPD, we were interested in the fraction with asthma
(and therefore contraindications to LABA therapy), for pa-
tients with claims-based COPD only, we were interested
in the fraction with true COPD (i.e., an appropriate indica-
tion for LABA therapy). For the latter set, we compared
categories of confirmed COPD vs. unconfirmed COPD to
identify the 3 most individually discriminating covariates.
We estimated 95% confidence intervals (CI) using the
exact binomial method.
We chose this categorization of asthma and COPD to
be useful for monitoring off-label prescribing of LABAs,
where it is of interest to know what fraction of patients
with claims for COPD truly have COPD (on-label use
—the latter set), and for patients with at least one
claim for asthma or for patients with no claim for
asthma or COPD, what fraction truly have asthma only
(off-label use—the former set). These analyses were re-
stricted to patients for whom we received a medical
record. Additionally, we tabulated these PPVs within
categories of a number of clinically derived variables
that could plausibly be associated with a different PPV
and within covariate patterns defined by the 3 most in-
dividually discriminating covariates.
We also conducted a post-hoc regression analysis as an
additional means to identify covariates whose presence
may modify the accuracy of the identification of asthma
or COPD. Using multinomial logistic regression models,
we regressed confirmed case status (asthma only, COPD
only, both, or neither, with neither as the referent) on
the claims definitions for these conditions, plus the co-
variates with product terms for each covariate and the
claims definitions. We retained an empirical approach to
covariate selection by using a stepwise algorithm, enter-
ing and retaining variables with p-values < 0.05.
Human subjects considerations
Since this study used protected health information
(PHI) to link insurance claims to patient’s medical
records, we operated with the oversight of the New
England Institutional Review Board who approved our
protocol, privacy practices, and whose Privacy Board
granted a waiver of authorization for the use of PHI
without obtaining patient consent.
Results
Of the 225,079 eligible initiators of a LABA, 9,965 (4.4%)
appeared to receive LABA monotherapy (Table 1). Users
of a LABA without concomitant ICS were more likely to
be ≥65 years of age, while there were no observed differ-
ences with respect to sex. Women accounted for nearly
two-thirds of patients with baseline claims for asthma,
while men accounted for over one-half of patients with
COPD. A total of 107,839 of the 225,079 (47.9%) patients
had no claim for asthma or COPD in the baseline period.
The distribution of number of diagnoses of asthma or
COPD in the baseline period was low, ranging from a
mean of 0.6 in the 0–90 days before the index date to 0.18
in the 91–183 days before the index date.
Patients on LABAs without ICS had a higher observed
prevalence of use of other pulmonary medications, in-
cluding inhaled anticholinergics, leukotriene modifiers,
and xanthine derivatives. Use of inhaled anticholinergics
was more prevalent among patients with baseline claims
for COPD, while use of leukotriene modifiers was more
common among patients with claims for asthma.
We sought 640 medical records related to 520 claims
consistent with asthma, COPD, both, or neither. One
hundred twenty of these records were requested from al-
ternate providers, when such an alternate was available
and the initial provider was unable or unwilling to
complete the request. We received medical records relat-
ing to 370 (71%) of potential cases. The Supplementary
Material contains information on the reasons for non-
procurement of medical records, which were generally ad-
ministrative in nature. Patients whose medical records we
received were slightly older than the underlying LABA co-
hort, but had a similar sex distribution (Table 2).
The PPV of having at least one claim for asthma (and
no COPD claim) in the 6 months prior to the index date
was 73.6% (CI 63.3–82.3) for confirmed asthma and
81.5% for COPD with no asthma claim (CI 72.1–88.9;
Table 3). We observed that 21.2% (CI 13.8–30.3) of pa-
tients with claims for asthma and COPD were confirmed
to have both conditions, while 28.9% of patients with no
claims for asthma or COPD (CI 19.5–39.9) were con-
firmed to have asthma. Regarding the negative predictive
value of claims for asthma and COPD, 61.5% (CI 50.1–
71.9) of patients without these diagnoses had no evi-
dence of the conditions in the medical record, while
28.9% (CI 19.5–39.9) had confirmed asthma and 9.6%
(CI 4.1–18.1) had confirmed COPD.
The PPV of having at least one claim for asthma de-
creased with increasing age, but the PPV of having of at
least one claim for COPD increased with age (Table 4).
Stratification on the 3 covariates with the largest individual
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http://www.biomedcentral.com/1471-2466/14/47Table 1 Select baseline demographic and clinical characteristics of initiators of long-acting β-agonist and patients with confirmed asthma or COPD status,
January 1, 2005 – December 31, 2008
LABA LABA & ICS Asthma COPD Asthma & COPD Neither Asthma nor COPD
(N=9,965) (N=215,114) (N= 87,864) (N=20,934) (N=8,442) (N=107,839)
N % N % N% N% N % N %
Age
20-39 2,081 20.9 65,018 30.2 33,717 38.4 758 3.6 673 8.0 31,951 29.6
40-64 6,230 62.5 130,968 60.9 50,206 57.1 13,775 65.8 5,895 69.8 67,322 62.4
>64 1,654 16.6 19,128 8.9 3,941 4.5 6,401 30.6 1,874 22.2 8,566 7.9
Women 5,962 59.8 131,390 61.1 56,437 64.2 9,913 47.4 5,103 60.5 65,899 61.1
Upper respiratory tract conditions
Sinusitis 1,812 18.2 42,469 19.7 20,310 23.1 2,828 13.5 1,794 21.3 19,349 17.9
Rhinitis 2,356 23.6 50,513 23.5 32,031 36.5 2,228 10.6 1,965 23.3 16,645 15.4
Tonsillitis 61 0.6 1,596 0.7 781 0.9 60 0.3 38 0.5 778 0.7
Nasopharyngitis and Pharyngitis 664 6.7 16,636 7.7 7,393 8.4 859 4.1 597 7.1 8,451 7.8
Laryngitis 109 1.1 2,062 1.0 797 0.9 197 0.9 125 1.5 1,052 1.0
Lower respiratory tract conditions
Asthma 4,095 41.1 92,211 42.9 87,864 100.0 0 0.0 8,442 100.0 0 0.0
COPD 2,428 24.4 26,948 12.5 0 0.0 20,934 100.0 8,442 100.0 0 0.0
Emphysema 593 6.0 4,633 2.2 230 0.3 3,452 16.5 1,159 13.7 385 0.4
Bronchitis/Bronchiolitis 3,096 31.1 74,688 34.7 25,329 28.8 11,954 57.1 5,745 68.1 34,756 32.2
Bronchiectasis 154 1.5 1,116 0.5 300 0.3 351 1.7 170 2.0 449 0.4
Pneumonia (viral or bacterial) 911 9.1 15,371 7.1 4,629 5.3 3,948 18.9 1,954 23.1 5,751 5.3
Other respiratory disease
Pleurisy 331 3.3 4,022 1.9 919 1.0 1,580 7.5 555 6.6 1,299 1.2
Pneumothorax 58 0.6 588 0.3 98 0.1 313 1.5 87 1.0 148 0.1
Respiratory failure 275 2.8 2,775 1.3 432 0.5 1,445 6.9 732 8.7 441 0.4
Pulmonary embolism 124 1.2 1,692 0.8 459 0.5 592 2.8 248 2.9 517 0.5
Pulmonary edema 154 1.5 2,411 1.1 629 0.7 780 3.7 344 4.1 812 0.8
Congestive heart failure 487 4.9 5,953 2.8 1,041 1.2 2,767 13.2 1,035 12.3 1,597 1.5
Malignant neoplasm of trachea, bronchus, and lung 200 2.0 1,714 0.8 167 0.2 976 4.7 203 2.4 568 0.5
Obstructive sleep apnea 224 2.2 3,202 1.5 1,217 1.4 710 3.4 388 4.6 1,111 1.0
Medication use
LABA
a 9,965 100.0 4,583 2.1 5,746 6.5 2,346 11.2 1,060 12.6 5,396 5.0
ICS 1,931 19.4 14,621 6.8 9,671 11.0 1,693 8.1 1,423 16.9 3,765 3.5
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7Table 1 Select baseline demographic and clinical characteristics of initiators of long-acting β-agonist and patients with confirmed asthma or COPD status,
January 1, 2005 – December 31, 2008 (Continued)
Fixed, combined LABA and ICS
a 988 9.9 212,605 98.8 83,675 95.2 19,127 91.4 7,730 91.6 103,061 95.6
Short-acting beta agonist 4,399 44.1 101,481 47.2 54,461 62.0 9,430 45.0 5,348 63.3 36,641 34.0
Inhaled anticholinergics 1,811 18.2 14,311 6.7 3,422 3.9 6,900 33.0 2,510 29.7 3,290 3.1
Combined SABA and inhaled anticholinergics 935 9.4 12,679 5.9 3,983 4.5 4,560 21.8 2,040 24.2 3,031 2.8
Injected or oral corticosteroids 3,684 37.0 76,198 35.4 36,436 41.5 9,249 44.2 5,509 65.3 28,688 26.6
Leukotriene modifiers 2,241 22.5 36,924 17.2 22,577 25.7 1,914 9.1 2,283 27.0 12,391 11.5
Mast cell stabilizers 74 0.7 369 0.2 281 0.3 17 0.1 21 0.2 124 0.1
Immunoglobulin-E blockers 64 0.6 340 0.2 335 0.4 4 0.0 42 0.5 23 0.0
Xanthine derivatives 320 3.2 2,142 1.0 936 1.1 599 2.9 445 5.3 482 0.4
Healthcare utilization
Ambulatory visit 9,340 93.7 204,687 95.2 87,834 100.0 20,895 99.8 8,432 99.9 96,866 89.8
Emergency department visit 2,278 22.9 46,120 21.4 20,083 22.9 6,764 32.3 3,950 46.8 17,601 16.3
Inpatient stay 1,258 12.6 18,729 8.7 6,334 7.2 5,784 27.6 3,357 39.8 4,512 4.2
Pathology/Laboratory code 6,724 67.5 140,407 65.3 58,592 66.7 15,357 73.4 6,504 77.0 66,678 61.8
Spirometry procedure 3,039 30.5 50,465 23.5 28,720 32.7 7,635 36.5 3,912 46.3 13,237 12.3
Home oxygen use procedure 783 7.9 6,704 3.1 1,461 1.7 3,402 16.3 1,214 14.4 1,410 1.3
Cardiovascular procedure 2,936 29.5 52,404 24.4 19,008 21.6 10,399 49.7 4,599 54.5 21,334 19.8
Surgical procedure 5,283 53.0 106,468 49.5 43,104 49.1 13,216 63.1 5,334 63.2 50,097 46.5
Anesthesia procedure 1,034 10.4 17,936 8.3 6,887 7.8 2,989 14.3 1,258 14.9 7,836 7.3
Visit to allergist/immunologist 1,111 11.1 17,759 8.3 14,522 16.5 311 1.5 689 8.2 3,348 3.1
Visit to pulmonologist 2,622 26.3 27,141 12.6 11,604 13.2 7,856 37.5 4,133 49.0 6,170 5.7
LABA, long-acting beta agonist; ICS, inhaled corticosteroid; COPD, chronic obstructive pulmonary disease.
aIncluding the cohort-defining dispensing.
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7discrimination between confirmed and unconfirmed case
status resulted in higher PPVs. For instance, among patients
with at least one claim for COPD and at least one dispens-
ing of an inhaled anticholinergic medication, the PPV was
94.3% (CI 80.8–99.3). Similar findings were evident for the
other empirically identified discriminators.
Stratification on clinically defined covariates resulted
in some categories where the PPV was higher than the
average PPV for that diagnosis (Table 5). The PPV for at
least one asthma claim was increased in the presence of
previous asthma medication use and lower respiratory
tract infections. The PPV for at least one COPD claim
was increased when a pulmonologist was the prescriber
of the COPD medications and when there was a diagno-
sis of bronchitis or bronchiolitis. The Supplementary
Material contains estimated PPVs across strata defined
by combinations of variables and for a long baseline
period of 12 months.
The multinomial logistic regression modeling identi-
fied several variables that improved prediction of true
case status through interaction with the claims defini-
tions. The variables “symptoms involving respiratory sys-
tem and other chest symptoms” (ICD-9 786.xx), the
number of baseline drug dispensings, and age >40 years
improved prediction of COPD only. The number of drug
dispensings also improved prediction of asthma only and
both asthma and COPD relative to neither. The presence
of a baseline dispensing of a beta-adrenergic drug and
the diagnosis “other forms of chronic ischemic heart
disease” (ICD-9 414.xx) improved prediction of true
asthma only. No other variables arose as significant
predictors.
Discussion
Subsets of LABA initiators with asthma, COPD, and
both conditions can be identified and differentiated
using claims data, although categorization of the
remaining patients is largely infeasible. Within strata of
selected covariates, the claims showed better predictive
ability to identify asthma only among patients with
claims for asthma or claims for both asthma and COPD,
and to identify COPD among patients with claims for
COPD. Among patients without claims for asthma or
COPD, there was no subset within which the PPV
exceeded 50%, meaning the classification of patients
who do not have a claim indicating asthma or COPD re-
mains uncertain. Additionally, requiring the presence of
claims for asthma or COPD resulted in a population in
which nearly 25% of persons appear to not have the con-
dition of interest.
That a substantial fraction of the LABA users did not
have a claim associated with asthma or COPD is prob-
lematic in that it leaves a large fraction of patients un-
classified in the data. Similarly, multiple diagnoses of
asthma or COPD were rare, limiting our ability to refine
the algorithms by requiring more than one diagnosis for
the condition of interest. Both of these findings are con-
sistent with previous experience with health plan data.
Table 3 Confirmed cases of asthma, chronic obstructive pulmonary disease, both, or neither among the corresponding
claims categories
Confirmed cases
Asthma COPD Asthma and COPD Unconfirmed
N% N% N % N %
Claims-identified cases Asthma (n =91) 67 73.6 2 2.2 0 0.0 22 24.2
COPD (n=92) 6 8.7 73 81.5 2 2.2 11 7.6
Both (n=104) 40 38.5 35 33.7 22 21.2 7 6.7
Neither (n= 83) 24 28.9 8 9.6 0 0.0 51 61.5
COPD, Chronic Obstructive Pulmonary Disease.
Table 2 Baseline age and gender of LABA initiators whose medical record was abstracted for confirmation of asthma
or COPD, January 1, 2005 – December 31, 2008
LABA LABA & ICS Asthma COPD Asthma & COPD Neither Asthma nor COPD
(N=14) (N=356) (N=91) (N=92) (N=104) (N=83)
N% N % N% N% N % N %
Age
20-39 2 14.3 49 13.8 24 26.4 4 4.4 6 5.8 17 20.5
40-64 11 78.6 242 68.0 62 68.1 58 63.0 76 73.1 57 68.7
>64 1 7.1 65 18.3 5 5.5 30 32.6 22 21.2 9 10.8
Women 8 57.1 210 59.0 57 62.6 50 54.4 60 57.7 51 61.5
LABA, long-acting beta agonist; ICS, inhaled corticosteroid; COPD, chronic obstructive pulmonary disease.
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http://www.biomedcentral.com/1471-2466/14/47Table 4 Positive predictive value of claims for asthma, COPD, Both or Neither in the 6 Months prior to initiation of a
long-acting beta agonist, Overall and stratified by empirically-identified covariates
Number of
confirmed cases
Medical records
received
Positive predictive
value (%)
95% CI (%)
Claim for asthma only
Overall 67 91 73.6 63.3, 82.3
Age, years
20-39 19 24 79.2 57.8, 92.9
40-64 45 62 72.6 59.8, 83.1
> 64 3 5 60.0 14.7, 94.7
Sex
Male 25 34 73.5 55.6, 87.1
Female 42 57 73.7 60.3, 84.5
Top 3 Variables predictive of asthma
confirmation
Outpatient visit, moderate complexity Yes 42 51 82.4 69.1, 91.6
No 25 40 62.5 45.8, 77.3
Beta-adrenergic drug dispensing Yes 53 66 80.3 68.7, 89.1
No 14 25 56.0 34.9, 75.6
West region Yes 18 19 94.7 74.0, 99.9
No 49 72 68.1 56.0, 78.6
Claim for COPD only
Overall 75 92 81.5 72.1, 88.9
Age, years
20-39 2 4 50.0 6.8, 93.2
40-64 44 58 75.9 62.8, 86.1
> 64 29 30 96.7 82.8, 99.9
Sex
Male 38 42 90.5 77.4, 97.3
Female 37 50 74.0 59.7, 86.4
Top 3 Variables predictive of COPD confirmation
65+ years of age Yes 29 30 96.7 82.8, 99.9
No 46 62 74.2 61.5, 84.5
Inhaled anticholinergic drug dispensing Yes 33 35 94.3 80.8, 99.3
No 42 57 73.7 60.3, 84.5
Radiologic examination, chest, 2 views,
frontal and lateral
Yes 48 54 88.9 77.4, 95.8
No 27 38 71.1 54.1, 84.6
Claim for Asthma and COPD (PPV of asthma only)
Overall 40 104 38.5 29.1, 48.5
Age, years
20-39 5 6 83.3 35.9, 99.6
40-64 30 76 39.5 28.4, 52.4
> 64 5 22 22.7 7.8, 45.4
Sex
Male 19 44 43.2 28.3, 59.0
Female 21 60 35.0 23.1, 48.4
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with a clear indication (irritable bowel syndrome), only
32% of tegaserod initiators had a claim for irritable
bowel syndrome in the 6-month period preceding tega-
serod initiation [12]. To address this expected feature of
the data, we abstracted medical records on a subset of
LABA initiators with no claims for asthma or COPD, and
confirmed their actual case status. The resulting data pro-
vide an estimate of the distribution of actual asthma and
COPD among those without a claims-diagnosis. Neverthe-
less, a large fraction of patients remain unclassified. In
studies of off-label use, this limitation means that there
will be overestimation of off-label use (under the assump-
tion that some of the unclassified patients have the
“on-label” indication). In studies where there is a desire
to exclude patients with asthma or COPD, it may be
infeasible to completely exclude these individuals.
Our findings were qualitatively similar to those in a
study of the predictive ability of the Lovelace Health
Plan data, a staff- and network-model health mainten-
ance organization, for identifying preclinical COPD [8].
In that study, a small number of claims-based variables
predicted the presence of preclinical COPD with a PPV
of 23% to 39% depending on the definition used. The
higher PPVs observed in our study probably reflect our
focus on diagnosed COPD, while the Lovelace study
screened for preclinical disease.
We did not directly assess the sensitivity of the claims
definition; however, the small number of LABA users
observed to have baseline claims for asthma or COPD
overall suggest that the sensitivity of the diagnosis codes
on claims may be low since nearly all LABA users would
be expected to have one of these conditions. Other limi-
tations of this study include the use of medical records
as a gold standard measure of asthma and COPD. This
approach requires the assumption that the information
needed for asthma and COPD classification is present
and not differentially present across the strata of the pre-
dictive variables. If the incorrect diagnosis is listed in the
medical record or the medical record is incomplete, then
the present estimates of the PPV could be biased. The
bias would likely result in an underestimate of the PPV
Table 4 Positive predictive value of claims for asthma, COPD, Both or Neither in the 6 Months prior to initiation of a
long-acting beta agonist, Overall and stratified by empirically-identified covariates (Continued)
Top 3 Variables predictive of asthma only among
patients with claims-based COPD and asthma
Chronic airway obstruction, not elsewhere
classified (ICD-9 496.xx)
Yes 20 76 26.3 16.9, 37.7
No 20 28 71.4 51.3, 86.8
General Bronchodilator Agents Yes 6 35 17.1 6.6, 33.6
No 34 69 49.3 37.0, 61.6
Inhaled corticosteroid dispensing Yes 9 39 23.1 11.1, 39.3
No 31 65 47.7 35.1, 60.5
No claims for asthma or COPD (PPV of asthma only)
Overall 24 83 28.9 19.5, 39.9
Age, years
20-39 7 17 41.2 18.4, 67.1
40-64 14 57 24.6 14.1, 37.8
> 64 3 9 33.3 7.5, 70.1
Sex
Male 8 32 25.0 11.5, 43.4
Female 16 51 31.4 19.1, 45.9
Top 3 Variables predictive of asthma only among
patients with neither claims-based COPD nor asthma
Lipid panel Yes 1 23 4.4 0.1, 21.9
No 23 60 38.3 26.1, 51.8
Collection of venous blood by venipuncture Yes 4 31 12.9 3.6, 29.8
No 20 52 38.5 25.3, 53.0
Macrolides Yes 4 29 13.8 3.9, 31.7
No 20 54 37.0 24.3, 51.3
COPD, chronic obstructive pulmonary disease.
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http://www.biomedcentral.com/1471-2466/14/47Table 5 Positive predictive value of claims for asthma, COPD, both or neither in the 6 months prior to initiation of a
long-acting beta agonist, overall and stratified by clinically-defined covariates
Number of
confirmed cases
Medical records
received
Positive predictive
value (%)
95% CI (%)
Claim for asthma only
Medications
Previous LABA 7 8 87.5 47.3, 99.7
Previous ICS 12 14 85.7 57.2, 98.2
Inhaled anticholinergics 0 0 0.0 N/A
Systemic corticosteroids 31 40 77.5 61.5, 89.2
Leukotriene modifiers 24 30 80.0 61.4, 92.3
Xanthine inhibitors 3 3 100.0 29.2, 100.0
Prescriber Specialty
Family/general provider 36 48 75.0 60.4, 86.4
Allergy/immunology 15 20 75.0 51.0, 91.3
Internal medicine 30 42 71.4 55.4, 84.3
Pulmonology 13 17 76.5 50.1, 93.2
Diagnoses
Upper respiratory tract infections 40 49 81.6 68.0, 91.2
Lower respiratory tract infection 67 91 73.6 63.3, 82.3
Bronchitis/Bronciolitis 19 24 79.2 57.8, 93.0
Spirometry procedure 26 33 78.8 61.1, 91.0
Claim for COPD Only
Medications
Previous LABA 3 5 60.0 14.7, 94.7
Previous ICS 4 4 100.0 39.8, 100.0
Inhaled anticholinergics 33 35 94.3 80.8, 99.3
Systemic corticosteroids 29 36 80.6 64.0, 91.8
Leukotriene modifiers 5 9 55.6 21.2, 86.3
Xanthine inhibitors 2 2 100.0 16.8, 100.0
Prescriber Specialty
Family/general provider 40 48 83.3 69.8, 92.5
Allergy/immunology 0 3 0.0 0.0, 70.6
Internal medicine 34 42 81.0 65.9, 91.4
Pulmonology 29 32 90.6 75.0, 98.0
Diagnoses
Upper respiratory tract infections 12 20 60.0 36.1, 80.9
Lower respiratory tract infection 75 92 81.5 72.1, 88.9
Bronchitis/Bronciolitis 51 59 86.4 75.0, 94.0
Spirometry procedure 32 39 82.1 66.5, 92.5
Claim for asthma and COPD (PPV of asthma only)
Medications
Previous LABA 3 12 25.0 5.5, 57.2
Previous ICS 4 14 28.6 8.4, 58.1
Inhaled anticholinergics 9 39 23.1 11.1, 39.3
Systemic corticosteroids 27 70 38.6 27.1, 51.0
Leukotriene modifiers 10 30 33.3 17.3, 52.8
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that cases have the diagnostic criteria affirmatively listed
in their record.
These data may not be generalizable to populations of
patients who do not use LABAs and caution is warranted
for applications of these data to patients with different
treatment patterns. Since our objective was to study LABA
initiators, we did not collected data on non-users of
LABA. Similarly, these data may not generalize to popula-
tions other than the commercially insured, but stratifying
this population according to relevant characteristics and
providing the PPV within strata, improves the external
application of these data for case identification [13]. Al-
though these characteristics for stratification are based on
health insurance claims in this study were, and so are sub-
ject to misclassification on the clinical constructs of inter-
est, this type of misclassification is frequently thought to
be non-differential with respect to other claims-based var-
iables so that the most plausible direction of misclassifica-
tion bias would be toward showing no difference in the
PPV across these variables [14]. In some strata of predict-
ive covariates, the data were sparse, which resulted in un-
certainty around some PPV estimates. Additionally, we
evaluated the performance of our own measure of asthma
and COPD. Therefore, these data may provide limited in-
formation on the validity of other disease definitions.
A major strength of this study is the large source popu-
lation, and its reflection of routine clinical practice across
the US. These data provide adequate statistical power for
the study across a number of stratification variables, and
improves its generalizability.
Because of low sensitivity, the claims data do not seem
sufficient to definitively identify asthma alone without sac-
rificing the PPV. However, this study provides estimates of
Table 5 Positive predictive value of claims for asthma, COPD, both or neither in the 6 months prior to initiation of a
long-acting beta agonist, overall and stratified by clinically-defined covariates (Continued)
Xanthine inhibitors 2 6 33.3 4.3, 77.7
Prescriber Specialty
Family/general provider 22 67 32.8 21.8, 45.4
Allergy/immunology 7 10 70.0 34.8, 93.3
Internal medicine 25 59 42.4 29.6, 55.9
Pulmonology 19 52 36.5 23.6, 51.0
Diagnoses
Upper respiratory tract infections 20 43 46.5 31.2, 62.3
Lower respiratory tract infection 40 104 38.5 29.1, 48.5
Bronchitis/Bronciolitis 28 72 38.9 27.6, 51.1
Spirometry procedure 21 53 39.6 26.5, 54.0
No claims for asthma or COPD (PPV of asthma only)
Medications
Previous LABA 0 4 0.0 0.0, 60.2
Previous ICS 0 2 0.0 0.0, 84.2
Inhaled anticholinergics 0 2 0.0 0.0, 84.2
Systemic corticosteroids 9 28 32.1 15.9, 52.4
Leukotriene modifiers 5 11 45.5 16.7, 76.6
Xanthine inhibitors 0 0 0.0 N/A
Prescriber specialty
Family/general provider 12 48 25.0 13.6, 39.6
Allergy/immunology 1 1 100.0 2.5, 100.0
Internal medicine 7 28 25.0 10.7, 44.9
Pulmonology 3 7 42.9 9.9, 81.6
Diagnoses
Upper respiratory tract infections 5 30 16.7 5.6, 34.7
Lower respiratory tract infection 6 33 18.2 7.0, 35.5
Bronchitis/Bronchiolitis 5 29 17.2 5.8, 35.8
Spirometry procedure 3 8 37.5 8.5, 75.5
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might expect from studies identified on the basis of claims
alone. For subsets of patients with claims for asthma or
COPD, the claims have fairly high predictive ability for
identifying actual diagnoses. Therefore, a reasonable use
of these data for LABA risk management is to estimate
the fraction of patients with asthma through application of
the observed distributions from this study, and to identify
subsets of these patients based on the presence of at least
one additional predictive covariate to achieve a higher de-
gree of specificity. This use of the data would allow for
periodic tracking of the fraction of potential off-label use
among a subset of patients likely to have asthma only,
while at the same time applying the observed (confirmed)
distribution of asthma only from this study for broader
context.
Conclusions
In summary, the results from this study suggest that it is
feasible to differentiate subsets of LABA initiators into
categories that might represent on- vs. off-label use of
LABAs. It is not possible to categorize all LABA initia-
tors with respect to these diagnoses. Safety surveillance
for off-label use of LABAs must account for this limita-
tion. Nevertheless, these data provide confirmed distri-
butions of actual diagnoses that can be extrapolated to
future surveillance studies and facilitate improved identi-
fication of subsets of patients with asthma, COPD, both,
or neither on the basis of health insurance claims data.
Implementation of simple algorithms that combine the
presence of a diagnosis code for asthma or COPD with
the presence or absence of a number of single PPV-
predictive covariates would allow for periodic tracking of
off-label LABA prescribing among subsets of all LABA
users. The specific algorithm chosen should be targeted
to the application at hand.
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